MTEC

Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brain Injuries

Retrieved on: 
Wednesday, April 5, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Manna, Therapy, Pharmacokinetics, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Patient, Brain, United States Army Medical Research and Development Command, Drug discovery, QPS, MTEC, Safety, Pharmaceutical industry

Astrocyte Pharmaceuticals Inc. , a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers.

Key Points: 
  • Astrocyte Pharmaceuticals Inc. , a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers.
  • This adaptive-design clinical study will be conducted over the next four to six months at the QPS clinical research site in Groningen, Netherlands.
  • A Phase 1A study completed in 2022 with single ascending 10-minute bolus doses of AST-004 showed no significant adverse effects or safety signals.
  • “Astrocyte is committed to developing innovative therapies that treat brain injuries and improve the lives of patients,” said Lisa Manna, Astrocyte’s Vice President of Clinical Development Operations.

EverGlade Consulting Founder, Eric Jia-Sobota, Announces Promotions, New Hires and 20% Growth in Q12023

Retrieved on: 
Tuesday, March 7, 2023
Forecasting, NSF, Clemson University, Financial management, Growth, Immunology, Small business, Accounting, Management consulting, Consultant, BARDA, Microbiology, DARPA, MTEC, Vanderbilt University, NIAID, MCDC, Management

CHARLESTON, S.C., March 7, 2023 /PRNewswire/ -- EverGlade Consulting ("EverGlade"), a national consulting firm, announces key promotions and new hires while achieving 20% growth in the first quarter of 2023.

Key Points: 
  • CHARLESTON, S.C., March 7, 2023 /PRNewswire/ -- EverGlade Consulting ("EverGlade"), a national consulting firm, announces key promotions and new hires while achieving 20% growth in the first quarter of 2023.
  • "These promotions are a direct reflection of the hard work and dedication our employees exhibit towards our team and our clients every day, said EverGlade Consulting President, Jerry Jia-Sobota.
  • In addition to promotions, EverGlade continues to grow with several key hires.
  • "I am excited that EverGlade continues to grow and prosper," said EverGlade Founder Eric Jia-Sobota.

Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Septic shock, OTA, Hypovolemia, Physician, United States Army Medical Research and Development Command, United States Army Medical Research Institute of Infectious Diseases, ECMO, Extracorporeal membrane oxygenation, Biomedical technology, Probability, Patient, Clinical trial, Shock, Inflammation, Food, Mortality, Nitric oxide, Shock (mechanics), Survival, Therapy, FDA, MTEC, NO, Food and Drug Administration, Bio, Blood pressure, Death, Kidney, Pharmaceutical industry

Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.

Key Points: 
  • Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.
  • Severe septic shock patients experience a drastic drop in blood pressure that is associated with multiple organ failure causing patient death.
  • While conventional fluids are effective for treating absolute hypovolemia, they are ineffective for treating relative hypovolemia, which is caused by excessive production of nitric oxide (NO) in septic shock.
  • In the VBI-S Phase IIa trial, reversal of relative hypovolemia led to an increase in blood pressure and improvement of organ function.

Athersys Provides MultiStem Clinical Update

Retrieved on: 
Monday, January 9, 2023
Stem Cells, Biotechnology, Manufacturing, Health, Pharmaceutical, Other Science, Research, Other Manufacturing, Genetics, Science, Clinical Trials, Ischemia, Internet, EMA, McGovern Medical School, European Medicines Agency, University, Blood, Tissue, TPA, Mitsubishi, World Stroke Organization, Autoimmunity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Regenerative medicine, Nature Reviews Neurology, Safety, University of Texas Health Science Center at Houston, FDA, Trauma, Inflammation, 3D, Department of Defense Serum Repository, Partnership, Houston Methodist Hospital, Conference, Protein, Central nervous system, FAHA, Resuscitation, Mitsubishi UFJ Financial Group, Weill Cornell Medicine, Food, Patient, Children's Memorial Hermann Hospital, State, Memorial Hermann–Texas Medical Center, Stroke, Trauma Center, Trauma center, MTEC, Pharmaceutical industry, Vaccine, Neurology

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).

Key Points: 
  • Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).
  • MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions.
  • MASTERS-2 is a company-sponsored Phase 3 randomized, double-blind, placebo-controlled trial evaluating MultiStem for the treatment of acute ischemic stroke.
  • Athersys’ enthusiasm about MultiStem for the treatment of ischemic stroke has been bolstered by results from completed clinical trials, and we look forward to providing updates on MASTERS-2 after we engage with regulatory authorities during the first quarter of 2023,” stated Dan Camardo, Chief Executive Officer of Athersys.

Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB® Hydrogel from the United States Department of Defense

Retrieved on: 
Tuesday, October 4, 2022
United States Army Medical Research and Development Command, U.S. Department of Defense Strategy for Operating in Cyberspace, GLOBE, Medicare, News, TSX Venture Exchange, Hydrogel, Unitary state, Wound healing, Technology, Research, Industry, Department, Health, Military personnel, Biomedical Research, Army, Failure, Death, Bacteria, Biomedical technology, MTEC, Sepsis, Safety, Policy, Amputation, Department of the Army Civilian Police, Acquisition, Disinfectant, Biofilm, Intellectual property, Department of Defence, Government, KNE, Company, Pharmaceutical industry, Medical imaging

This additional funding supplements the approximately $2.7 million USD in non-dilutive funding previously awarded for the continued clinical development of Kanes DispersinB Hydrogel to treat biofilm-mediated antimicrobial resistance in non-healing chronic wounds.

Key Points: 
  • This additional funding supplements the approximately $2.7 million USD in non-dilutive funding previously awarded for the continued clinical development of Kanes DispersinB Hydrogel to treat biofilm-mediated antimicrobial resistance in non-healing chronic wounds.
  • Our DispersinB Hydrogel pre-clinical results were very compelling and our upcoming clinical trials should further demonstrate the potential of DispersinB Hydrogel as an advanced treatment for non-healing chronic wounds, stated Marc Edwards, President and Chief Executive Officer of Kane Biotech.
  • DispersinB Hydrogel has shown great promise to inhibit biofilm formation, with the potential to promote wound closure and ultimately, accelerate return to duty.
  • StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech Inc.

Eight Winners of the 2022 Medical Innovation Challenge Announced at Defense TechConnect Innovation Summit & Expo

Retrieved on: 
Thursday, September 29, 2022
Hospital, University, Convention center, Global Innovation through Science and Technology initiative, Therapy, MTEC, Department, Saliva, Brain, Acquisition, Compliance, Centre for the Advancement of Sustainable Medical Innovation, Partnership, Industry, Stroke, Government, Infection, Mental health, Intelligence, ATI, Defense, Student, Technology, LAUNCH (Innovation Challenge), ANSER, Solution, Extracellular matrix, MCDC, Defence Analytical Services and Advice, Anxiety, Ultimate tensile strength, Atrial fibrillation, DTC, Music, Research, U.S. Department of Defense Strategy for Operating in Cyberspace, SHIC, Bone fracture, Depression, Medical imaging, Mobile phone, Pharmaceutical industry, Security (finance), Mass

WASHINGTON,  Sept. 29, 2022  /PRNewswire-PRWeb/ -- Advanced Technology International (ATI), TechConnect and four medtech industry consortia today announced the seven winners of the 2022 Medical Innovation Challenge as well as an eighth winner from innovations created by students. Selected from a field of 25 finalists, winners were presented a total $250,000 in cash prizes at the Defense TechConnect (DTC) Innovation Summit & Expo, the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements.

Key Points: 
  • WASHINGTON, Sept. 29, 2022 /PRNewswire-PRWeb/ -- Advanced Technology International (ATI), TechConnect and four medtech industry consortia today announced the seven winners of the 2022 Medical Innovation Challenge as well as an eighth winner from innovations created by students.
  • Selected from a field of 25 finalists, winners were presented a total $250,000 in cash prizes at the Defense TechConnect (DTC) Innovation Summit & Expo , the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements.
  • The Defense TechConnect (DTC) Innovation Summit & Expo is the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements.
  • DTC is proud to be one of the original innovation hubs to support the Department of Defense and its missions.

Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium

Retrieved on: 
Wednesday, September 14, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, U.S. Defense Department firefighters, Therapy, United States Army Medical Research and Development Command, Traumatic brain injury, Trial of the century, Safety, Department, MTEC, Policy, Department of Defence, Research, Army, Concussion, Stroke, Government, Patient, Merrell Dow Pharmaceuticals Inc. v. Thompson, Goal, TBI, Brain, Drug discovery, Neurodegeneration, Department of the Army Civilian Police, Pharmaceutical industry, Risk management, Astrocyte

Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held in Orlando, FL.

Key Points: 
  • Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held in Orlando, FL.
  • Our first single-dose Phase 1 clinical study is proceeding as planned, and we have now completed all dose levels in the healthy volunteer subjects.
  • TBI is a top health priority of the military; 22 percent of all combat casualties in recent years are brain injuries, remarked retired Colonel Dallas Hack, M.D., M.P.H., and advisor to Astrocyte.
  • Astrocyte Pharmaceuticals Inc. is a privately held, clinical stage, drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients.

New Antiviral Therapy May Block COVID-19 Transmission

Retrieved on: 
Friday, September 9, 2022
National, COVID-19, MTEC, University of California, San Francisco, Human, Technology, University, State, UC, SAN, Vaccine, Doctor of Philosophy, Time, Communication, Virus, Infection, Joint, TIP, Tips, Respiratory system, Scripps Research, Cell, Multimedia, HIV, Biophysics, Animal, Severe acute respiratory syndrome coronavirus 2, University of California, San Diego, National academy, Center, FDA, Aerosol, Drug resistance, Gladstone Institutes, Biochemistry, Clinical trial, Viral load, Media contacts database, Mark (given name), Pharmaceutical industry, William Ewart Gladstone, Delta

SAN FRANCISCO, Sept. 9, 2022 /PRNewswire/ -- By the time you test positive for COVID-19, the SARS-CoV-2 virus has already taken up residence in your respiratory system. With each breath, you expel invisible viral particles into the air—a process known as viral shedding. Existing drugs aimed at treating COVID-19, even when they address symptoms of the virus, do little to quell viral shedding.

Key Points: 
  • Existing drugs aimed at treating COVID-19, even when they address symptoms of the virus, do little to quell viral shedding.
  • "Historically, it has been exceptionally challenging for antivirals and vaccines to limit the transmission of respiratory viruses, including SARS-CoV-2," says Gladstone Senior Investigator Leor Weinberger, PhD, senior author of the new paper.
  • The researchers treated hamsters infected with SARS-CoV-2 with the antiviral TIPs and then measured, daily, the amount of virus in the animals' noses.
  • "So, being able to reduce SARS-CoV-2 transmission in this animal setting is quite promising for being able to reduce human-to-human transmission."

Defense TechConnect 2022 Innovation Summit & Expo to Feature Six Innovation Challenges for Accelerating Cutting-edge Technologies to Support the National Defense Strategy

Retrieved on: 
Thursday, September 8, 2022
National Science Foundation, MTEC, Technology, Science, Research, Convention center, Consortium, National Harbor, Maryland, DTC, National Security Innovation Network, ATI, ANSER, University, Global Innovation through Science and Technology initiative, Government, Engineering statistics, Department, Intelligence, U.S. Department of Defense Strategy for Operating in Cyberspace, Defense, Create, Industry, Defence Analytical Services and Advice, Partnership, National Center for Telehealth & Technology, Mass, VLC, Investment, Acceleration, SBIR, Privacy, Homeland, RISE, ADC, Acquisition, HSTC, Aviation, AI, Immersion, Artificiality, NSC, MCDC, LAUNCH (Innovation Challenge), Therapy, SHIC, Video game, Management, Security (finance), Pharmaceutical industry, Medical device, MD

WASHINGTON, Sept. 8, 2022   /PRNewswire-PRWeb/ -- 

Key Points: 
  • To be held Sept. 27-29, 2022, the Defense TechConnect 2022 Innovation Summit & Expo's six Innovation Challenges will feature "Shark Tank"-style pitches by startups, universities and national labs competing for more than $500,000 in total prizes.
  • The Defense TechConnect (DTC) 2022 Innovation Summit & Expo , the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements, will convene on Sept. 27-29, 2022, at Gaylord National Hotel & Convention Center, 201 Waterfront St., National Harbor, MD.
  • DTC also will feature its own innovation spotlights program featuring universities and startups presenting over the three-day program."
  • The Defense TechConnect (DTC) Innovation Summit & Expo is the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements.

Medical Innovation Challenge Announces Contenders For $200,000 Award

Retrieved on: 
Thursday, August 11, 2022
Multimedia, ATI, ANSER, Industry, Defence Analytical Services and Advice, Challenge, Government, Doctor of Philosophy, Global Innovation through Science and Technology initiative, View, SHIC, Partnership, MTEC, Federation, Entrepreneurship, Pharmaceutical industry, Research

"Prototype advancement of medical technology will undoubtedly have a profound impact on the capabilities that we are able to provide far forward in a military setting.

Key Points: 
  • "Prototype advancement of medical technology will undoubtedly have a profound impact on the capabilities that we are able to provide far forward in a military setting.
  • For more information about this Challenge or to register to attend, visit: https://events.techconnect.org/DTCFall/medical_innovation_challenge/ .
  • With 25+ years of experience connecting emerging technologies with unique funding and partnership opportunities, TechConnect boasts the most robust research and innovation network in the world.
  • It employs a broad scope of tools to deliver top technologies, including open innovation programs, conferences, and open-access publications.